Current perspectives on the diagnosis and management of fatigue in multiple sclerosis. (3rd August 2022)

• Record Type: Journal Article
• Authors: Marchesi, Olga; Vizzino, Carmen; Filippi, Massimo; Rocca, Maria A.
• Is Part Of: Expert review of neurotherapeutics. Volume 22:Number 8(2022)
• Page Start: 681
• Page End: 693
• Publication Date: 2022-08-03
• Subjects: Fatigue -- fatigability -- multiple sclerosis -- assessment -- pathophysiology -- fatigue treatment; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2022.2106854
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction: Fatigue is a common and debilitating symptom among multiple sclerosis (MS) patients with a prevalence up to 81% and with a considerable impact on quality of life. However, its subjective nature makes it difficult to define and quantify in clinical practice. Research aimed at a more precise definition and knowledge of this construct is thus continuously growing. Areas covered: This review summarizes the most relevant updates available on PubMed up to 1 July 2022 regarding: the assessment methods that aim to measure the concept of fatigue (as opposed to fatigability), the possible treatment pathways currently available to clinicians, interconnection with the pathophysiological substrates and with the common comorbidities of MS, such as depression and mood disorders. Expert opinion: The in-depth study of fatigue can help to better understand its actual impact on MS patients and can stimulate clinicians toward a more valid approach, through a targeted analysis of this symptom. Considering fatigue from a multidimensional perspective allows the use of patient-tailored methods for its identification and subsequent treatment by different professional figures. Better identification of methods and treatment pathways would reduce the extremely negative impact of fatigue on MS patients' quality of life.